Evenamide Hydrochloride

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- $NWRN #Biotech -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that Stefan Weber, CEO and Roberto Galli, CFO , will participate in the following investor conferences in June: Jefferies Global Healthcare Conference , June 2–4, 2026, New York H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference , June 15–16, 2026, Virtual At the Jefferies Global Healthcare Conference, members of the Newron management team will participate in a corporate presentation and one-on-one investor meetings. The corporate presentation will take place on Thursday, June 4, 2026, at 2:00 p.m. ET. At the H.C. Wainwright conference, members of the Newron team will participate virtually in a corporate presentation and one-on-one investor meetings. The pre-recorded corporate presentation will be available on-demand to registered conference attendees starting on June 15, 2026 at 7:00 A.M. (ET). To schedule a meeting with management during the conferences, please contact Casey Darby at cdarby@lavoiegroup.com . About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron’s partner, Zambon, with Supernus Pharmaceuticals holding marketing rights in the USA, and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: and connect with us on LinkedIn . Contacts Newron Stefan Weber – CEO +39 02 6103 46 26 pr@newron.com UK/Europa Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting +44 20 3727 1000 SCnewron@fticonsulting.com Switzerland Valentin Handschin, IRF +41 43 244 81 54 handschin@irf-reputation.ch Germany/Europa Anne Hennecke / Maximilian Schur, MC Services +49 211 52925227 newron@mc-services.eu USA Casey Darby, LaVoieHealthScience +1 617 351 0244 cdarby@lavoiegroup.com

🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as $AVLN on the Nasdaq Thursday with the offering expected to close Friday. It had originally targeted a $182 million IPO. Avalyn is advancing inhaled treatments for rare respiratory diseases. Its lead candidate, called AP01, is in Phase 2 development for progressive pulmonary fibrosis. The company has 51 full-time employees, according to an SEC filing . – Ayisha Sharma 🛑 Alector ends study for GSK-partnered Alzheimer’s drug: The California biotech said it is ending a Phase 2 trial of nivisnebart after an independent committee found it was unlikely to meet the primary endpoint. GSK and Alector plan to discuss their collaboration, which was signed in 2021 and included $1.5 billion in potential milestones. In October last year, another GSK-partnered candidate called latozinemab flunked a Phase 3 study in dementia. Alector’s first-generation antibody-based neurology platform had a separate disappointment in November 2024, when its AbbVie-partnered candidate AL002 failed a Phase 2 Alzheimer’s trial. – Ayisha Sharma 🤝 Teva to acquire Tourette’s drug company for $700M upfront: At the heart of the deal is Emalex’s ecopipam, which is on track for an NDA filing in the second half of the year. Emalex is also eligible for up to $200 million in commercial milestones and royalties. The acquisition reflects Teva’s strategy of focusing on clinically de-risked assets that are “synergistic” with its broader neurology pipeline, CEO Richard Francis told Endpoints News in an interview. But Jefferies analysts wrote that “IP is unclear, given [ecopipam is] an old drug.” – Ayisha Sharma ⏸️ FDA places clinical hold on Newron’s schizophrenia drug: The decision came after the company flagged the sudden death of a patient enrolled in the Phase 3 ENIGMA-TRS 2 trial outside of the US. Newron said an independent board assessed the event and concluded the study should continue as is. The company added it is working to supply the FDA with the necessary information to get the hold lifted. Evenamide targets voltage-gated sodium channels. Newron has previously touted the drug’s strong safety profile as a potential differentiator from standard-of-care antipsychotics. – Ayisha Sharma Merck has discontinued an anti-CTLA-4 program: Known as MK-1308A, the fixed-dose coformulation included Keytruda plus the anti-CTLA-4 antibody quavonlimab. The treatment was part of Merck’s Litespark-012 study that examined combinations with Lenvima in first-line renal cell carcinoma. Merck announced earlier this month that both the MK-1308A regimen and a separate regimen involving Merck’s Welireg failed. — Lei Lei Wu Leo Pharma buys gene therapy player Replay : The deal is for $50 million upfront, and nets Leo a preclinical HSV-based gene therapy for dystrophic epidermolysis bullosa. Replay launched in 2022 with $55 million in seed funding as a hub-and-spoke gene therapy company. — Lei Lei Wu AstraZeneca gets a new protein degrader: The British pharma will license a bispecific antibody degrader from Pinetree Therapeutics, under a $500 million deal inked back in 2024. The candidate, called PTX-299, targets EGFR and has made “encouraging preclinical progress,” the companies announced on Thursday. The move triggers a $25 million payment to Pinetree, and gives AstraZeneca responsibility for future development and commercialization. — Nicole DeFeudis